Related Experiment Videos
Left ventricular hypertrophy and angiotensin II receptor blocking agents.
K Yasunari1, K Maeda, M Nakamura
1Department of Medicine and Cardiology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan. yasunari@med.osaka-cu.ac.jp
Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|January 11, 2005
Summary
Angiotensin II promotes left ventricular hypertrophy (LVH), increasing cardiovascular risks. Angiotensin receptor blockers (ARBs) effectively treat LVH by blocking AT1 receptors, offering cardioprotection similar to ACE inhibitors.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Molecular Biology
Background:
- Angiotensin II significantly contributes to cell growth and proliferation, driving left ventricular hypertrophy (LVH).
- LVH is a major risk factor for severe cardiovascular events, including heart failure, stroke, and sudden death.
- Existing treatments like ACE inhibitors and ARBs show benefits in regressing LVH and improving cardiac remodeling.
Purpose of the Study:
- To review the evidence for Angiotensin II's role in promoting LVH.
- To present the mechanisms behind the beneficial effects of ARBs on LVH.
- To discuss findings from large-scale clinical trials evaluating ARBs.
Main Methods:
- Review of existing literature on Angiotensin II signaling and LVH.
- Analysis of studies investigating ARB mechanisms, including reactive oxygen species involvement.
- Presentation of results from major clinical trials like LIFE and VALUE.
Main Results:
- Angiotensin II signaling pathways are implicated in LVH development and dysregulation.
- ARBs demonstrate cardioprotective effects, potentially through complete AT1 receptor blockade.
- Costimulation of the AT2 receptor may induce beneficial bradykinin-like effects via nitric oxide.
Conclusions:
- ARBs offer significant benefits for LVH regression and cardiac remodeling.
- Complete blockade of the AT1 receptor is key to the therapeutic effects of ARBs.
- Further research and clinical data support the use of ARBs in high-risk cardiovascular patients.